It is not clear who at J1 will be the first to take the vaccine as the COVID-19 vaccination kicks up today.
It is not clear who at J1 will be the first person to take the vaccine.
The national COVID-19 vaccination campaign will be launched today at the J1 presidential palace in Juba. The first phase of the program that targets 2% of the national population, will be conducted by the national ministry of health in partnership with the World Health Organization and other health partners.
The incident Manager for Covid19 in the Ministry of Health Richard Laku says the vaccination exercise will kick off with front-line health workers at three centers which include J1, Juba Hospital, and Juba Military Hospital.
Dr. Laku says 60 health workers have been trained to administer the vaccines. The number of CIVID-19 cases is now more than ten thousand with 108 deaths registered by the ministry of health since the pandemic was declared in March last year.
South Sudan secured the first 132,000 doses of the coronavirus vaccines that arrived in the country on Thursday.
The AstraZeneca vaccines were delivered through the Gavi COVAX Advance Market Commitment. It is a global initiative to support equitable access to coronavirus vaccines. The first batch is part of the 2.4 million doses that South Sudan requested from COVAX.
It will also be given to people with underlying conditions such as cancer, asthma, and heart disease, among others. According to health officials, the launch at the State House will boost public trust in the treatment.
The Presidency is composed of President Salva Kiir, First Vice President Dr. Riek Machar, Vice Presidents; Nyandeng Garang, Dr. James Wani Igga, Abdelbaggi Ayii, and Taban Deng.
All the Vice Presidents, except President Kiir, have in the past months contracted the coronavirus.
“So we will see some leadership there if you go tomorrow.”
Each person will first receive 0.5 militre and the second jab after eight to twelve weeks.
For a 12 million population in South Sudan, only 732,000 AstraZeneca doses have so far been approved by COVAX because it said the demand for the dose globally is high, and the production is low.